Cargando…

PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma

High-grade serous ovarian carcinoma (HGSOC) is the most lethal type of gynecologic malignancy. Chemoresistance is the main reason for the poor prognosis of HGSOC. PDZ-binding kinase (PBK) promotes the malignant progression of various carcinomas. However, the roles and clinical significance of PBK in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hanlin, Li, Yingwei, Wang, Xiangxiang, Wu, Huan, Qi, Gonghua, Li, Rongrong, Yang, Ning, Gao, Min, Yan, Shi, Yuan, Cunzhong, Kong, Beihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379381/ https://www.ncbi.nlm.nih.gov/pubmed/30778048 http://dx.doi.org/10.1038/s41419-019-1415-6

Ejemplares similares

TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021)

PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

FBLN5 is targeted by microRNA-27a-3p and suppresses tumorigenesis and progression in high-grade serous ovarian carcinoma
por: Li, Rongrong, et al.
Publicado: (2020)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022)

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
por: Jank, Paul, et al.
Publicado: (2023)

Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk
por: Yuan, Cunzhong, et al.
Publicado: (2020)

IQGAP3 promotes cancer proliferation and metastasis in high-grade serous ovarian cancer
por: Dongol, Samina, et al.
Publicado: (2020)

Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer
por: Wang, Qiuman, et al.
Publicado: (2022)

miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2014)

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
por: Dou, Zhiyuan, et al.
Publicado: (2022)

RECQL4, Negatively Regulated by miR-10a-5p, Facilitates Cell Proliferation and Invasion via MAFB in Ovarian Cancer
por: Guo, Li, et al.
Publicado: (2020)

HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway
por: Ma, Hanlin, et al.
Publicado: (2023)

ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment
por: Ye, Xiang, et al.
Publicado: (2021)

CCNG1 (Cyclin G1) regulation by mutant‐P53 via induction of Notch3 expression promotes high‐grade serous ovarian cancer (HGSOC) tumorigenesis and progression
por: Xu, Ying, et al.
Publicado: (2018)

Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma
por: Dong, Ruifen, et al.
Publicado: (2016)

Tubal Origin of “Ovarian” Low-Grade Serous Carcinoma: A Gene Expression Profile Study
por: Wang, Yiying, et al.
Publicado: (2019)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

The MTDH (−470G>A) Polymorphism Is Associated with Ovarian Cancer Susceptibility
por: Yuan, Cunzhong, et al.
Publicado: (2012)

Analyzing Association of the XRCC3 Gene Polymorphism with Ovarian Cancer Risk
por: Yuan, Cunzhong, et al.
Publicado: (2014)

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer
por: Zheng, Zhi-Guo, et al.
Publicado: (2016)

Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer
por: Noriega-Rivera, Ricardo, et al.
Publicado: (2022)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Expression of the zinc finger gene EVI-1 in ovarian and other cancers.
por: Brooks, D. J., et al.
Publicado: (1996)

PBK/TOPK: A Therapeutic Target Worthy of Attention
por: Han, Ziping, et al.
Publicado: (2021)

Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer
por: Pan, Jianbo, et al.
Publicado: (2020)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study
por: Chen, Zhongshao, et al.
Publicado: (2022)

An Integrative Pan-Cancer Analysis of PBK in Human Tumors
por: Wen, Huantao, et al.
Publicado: (2021)

PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
por: Zhu, Kejing, et al.
Publicado: (2022)

Beclin-1 expression is retained in high-grade serous ovarian cancer yet is not essential for autophagy induction in vitro
por: Correa, Rohann J. M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bdusc7qjcfa271r2t3g8viqqtg